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Silibinin
Where Is the Ethical Conundrum?
To the Editor:
We read with great interest the recent article by Gores et al 1 in CHEST (October 2014). While applauding the suc cessful outcome of Amanita mushroom poisoning, it mystifi es us that the authors perceived any ethical quandary concerning the use of silibinin. We would consider it more ethically questionable to deprive the patient an opportunity to receive silibinin.
Silibinin is the treatment best supported by available canine 2 , 3 and human evidence. 4 -6 It has long been approved in Europe, where it is the drug of choice for amatoxin poisoning. While the market for silibinin in the United States is too small to justify eff orts by the manufacturer to pursue US Food and Drug Administration approval, the drug is essentially available for compassionate use under the National Institutes of Health-registered study protocol referenced in the original case report. 7 We recognize the rationale for IV N-acetylcysteine, IV penicillin G, and multidose-activated charcoal. All three have low risk and a modest role in treatment of amatoxin poisoning, but evidence of their effi cacy is weak to nonexistent.
Th e authors seem concerned about the botanical origins of the drug. We point out that we have no anxiety about using other drugs derived from plants such as the willow and the poppy in our daily practice.
Most patients with amatoxin poisoning survive, and it is impossible to say whether this patient's outcome would have been diff erent without silibinin. Given the available evidence, we would want silibinin if we were inadvertently poisoned with amatoxin-containing mushrooms. We thank the authors for their interest in our ethical dilemma 1 and for giving us another opportunity to emphasize our message. When faced with a patient with hepatic failure following Amanita poisoning, we chose to off er treatment with the investigational drug silibinin. 1 In doing so, we sought to balance its risks and benefi ts, attributes that we found diffi cult to quantify. Th e evidence making silibinin the "treatment best supported" relies on animal studies alone. Publications reporting use in patients include only uncontrolled case reports or series in which all subjects were treated with the drug. 2 -4 Th is is thin ice, indeed. On balance, we chose to
off er the drug but found that we wrestled with our decision.
We have little doubt that many clinicians would, like these authors, see no conundrum. But we were troubled by our inclination to action, knowing that sometimes doing nothing is the best medicine. 5 , 6 When faced with uncertainty, physicians oft en choose action over inaction, for many psychologic, medicolegal, and other reasons. But "clinical inertia" may serve to protect unwitting patients from our own overzealous attempts to help. 7 In their closing paragraph, the authors justify our concern: Th ey "want silibinin. " Th at is exactly the problem we hoped to illuminate.
